Patient Experience Report: Volume 2

The Patient Journey: Discovery, Experience, and Attitudes Towards GLP-1 RAs and SGLT-2 Inhibitors Treatment

We've tapped into our patient database, comprising over 65,000 individuals living with diabetes, to understand how GLP-1 RAs and SGLT-2 Inhibitors are impacting patients weight loss, their sentiment towards the pharmaceutical companies making the treatments, and the correlation between cost and adherence.

What you get

This report includes insights from:

1,500+ US adults with type 2 diabetes
40% non-white participants
50% male / 50% female respondents

The Patient Journey: Discovery, Experience, and Attitudes Towards GLP-1 RAs and SGLT-2 Inhibitors Treatment

What you get

Related Content

The Human Element in Data Management: Why Empathy Matters

$5B vs $500M Companies: How the Biggest Players in Diabetes Care Approach Market Research Differently

Are the decisions you are making built on trustworthy data?